Finding a treatment:
Acceleron will not conduct further clinical trials of ACE-083 in FSHD (https://www.fshdsociety.org/2019/09/16/disappointing-news-from-acceleron/)
Facio announces completion of real-world data study in FSHD (https://www.facio-therapies.com/news/facio-announces-completion-of-real-world-data-study-in-fshd/)
miRecule, Inc., is developing a novel treatment for FSHD (https://www.fshdsociety.org/2019/11/08/mirecule-inc-is-developing-a-novel-treatment-for-fshd/)
DUX4 is misexpressed in tumors, where it suppresses anti-tumor immune activity (link to full article).